During this discussion, Scott Gottlieb, MD; Michael Kolodziej, MD; and Ted Okon, MBA, further discuss how various reimbursement models are impacting clinical practice in oncology.
Dr Gottlieb begins by explaining why the CMS stepped in to regulate the practice of medicine by implementing additional rules regarding the provision of oncology products.
Healthcare reform has impacted oncology care in the United States in many ways, including the establishment of oncology medical homes and the implementation of payment reform models, remarks Mr Okon. He also describes differences in drug pricing in the community setting versus the hospital setting, and discusses the so-called drug incentive.
When establishing measures to help improve current healthcare models, various stakeholders should collaborate and discuss opportunities for achieving optimal efficiency, suggests Mr Okon. Stakeholders also need to work together to improve the reimbursement model for oncology services.
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More